Thioredoxin-interacting protein controls cardiac hypertrophy through regulation of thioredoxin activity

Circulation. 2004 Jun 1;109(21):2581-6. doi: 10.1161/01.CIR.0000129771.32215.44. Epub 2004 May 3.

Abstract

Background: Although cellular redox balance plays an important role in mechanically induced cardiac hypertrophy, the mechanisms of regulation are incompletely defined. Because thioredoxin is a major intracellular antioxidant and can also regulate redox-dependent transcription, we explored the role of thioredoxin activity in mechanically overloaded cardiomyocytes in vitro and in vivo.

Methods and results: Overexpression of thioredoxin induced protein synthesis in cardiomyocytes (127+/-5% of controls, P<0.01). Overexpression of thioredoxin-interacting protein (Txnip), an endogenous thioredoxin inhibitor, reduced protein synthesis in response to mechanical strain (89+/-5% reduction, P<0.01), phenylephrine (80+/-3% reduction, P<0.01), or angiotensin II (80+/-4% reduction, P<0.01). In vivo, myocardial thioredoxin activity increased 3.5-fold compared with sham controls after transverse aortic constriction (P<0.01). Aortic constriction did not change thioredoxin expression but reduced Txnip expression by 40% (P<0.05). Gene transfer studies showed that cells that overexpress Txnip develop less hypertrophy after aortic constriction than control cells in the same animals (28.1+/-5.2% reduction versus noninfected cells, P<0.01).

Conclusions: Thus, even though thioredoxin is an antioxidant, activation of thioredoxin participates in the development of pressure-overload cardiac hypertrophy, demonstrating the dual function of thioredoxin as both an antioxidant and a signaling protein. These results also support the emerging concept that the thioredoxin inhibitor Txnip is a critical regulator of biomechanical signaling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / pharmacology
  • Animals
  • Aortic Diseases / complications
  • Cardiomegaly / etiology
  • Cardiomegaly / genetics
  • Cardiomegaly / metabolism*
  • Carrier Proteins / genetics
  • Carrier Proteins / physiology*
  • Cell Cycle Proteins
  • Cell Size
  • Cells, Cultured / drug effects
  • Cells, Cultured / metabolism
  • Cells, Cultured / pathology
  • Constriction, Pathologic / complications
  • Disease Models, Animal
  • Genetic Vectors / genetics
  • Genetic Vectors / pharmacology
  • Heart / drug effects*
  • Ligation
  • Male
  • Myocardium / metabolism*
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism*
  • Myocytes, Cardiac / pathology
  • Oxidation-Reduction
  • Phenylephrine / pharmacology
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Reactive Oxygen Species
  • Signal Transduction
  • Single-Blind Method
  • Stress, Mechanical
  • Thioredoxins / genetics
  • Thioredoxins / metabolism*
  • Transcriptional Activation / drug effects
  • Transcriptional Activation / physiology

Substances

  • Carrier Proteins
  • Cell Cycle Proteins
  • Reactive Oxygen Species
  • TXNIP protein, rat
  • Angiotensin II
  • Phenylephrine
  • Thioredoxins